IKS-012

N/A

Report date: 2024/02/05 14:07:45

Base Information

Drug NameIKS-012

Drug Alias NameIKS-012

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-FOLR1

TargetsFolate receptor alpha

Therapy Area/IndicationsLung NeoplasmsOvarian NeoplasmsTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIksuda Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesIksuda Therapeutics

Inactive CompaniesN/A

Active IndicationsLung NeoplasmsOvarian NeoplasmsTriple Negative Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A